Analyzing Vicarious Surgical (NYSE:RBOT) and Nuwellis (NASDAQ:NUWE)

Vicarious Surgical (NYSE:RBOT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vicarious Surgical and Nuwellis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1	2	0	0	1.67
Nuwellis	1	0	0	0	1.00

Vicarious Surgical currently has a consensus price target of $7.00, suggesting a potential upside of 614.29%. Given Vicarious Surgical’s stronger consensus rating and higher probable upside, research analysts plainly believe Vicarious Surgical is more favorable than Nuwellis.

Institutional and Insider Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 9.5% of Vicarious Surgical shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Vicarious Surgical and Nuwellis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22 million	($6.69)	-0.15
Nuwellis	$8.27 million	0.28	-$17.52 million	($64.02)	-0.01

Nuwellis has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vicarious Surgical has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Profitability

This table compares Vicarious Surgical and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Nuwellis	-214.90%	-32,351.83%	-249.08%

Summary

Vicarious Surgical beats Nuwellis on 9 of the 12 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.